BACKGROUND: TGFbeta is an important cell growth regulator which may have a role in metastasis formation. Microsatellite unstable (MSI-H) colon cancer serves as a unique model to demonstrate this as most MSI-H colon cancers have a mutation in the transforming growth factor beta receptor II (TGFbetaRII) gene and a low metastatic rate. AIMS: To demonstrate an increase in invasion and metastasis in a MSI-H colorectal cancer cell line with a known mutation in TGFbetaRII. MATERIALS AND METHODS: By restoring the wild-type TGFbetaRII gene in the KM12C MSI-H colorectal carcinoma cell line with a known mutation in TGFbetaRII, we have demonstrated that both invasion and metastasis in this cell line was significantly increased. A mouse metastatic model have shown that liver metastases were increased in mice inoculated with cells containing a wild-type TGFbetaRII gene (42% for the transfected group compared with 15% for the control group; p = 0.0379), despite a reduction in the size of primary tumours. CONCLUSIONS: This study highlights an important mechanism which may contribute to the low metastatic rate of MSI-H colon cancers and demonstrates the importance of TGFbeta signalling in metastasis formation. Previous studies involving breast cancer cell lines have shown that blocking TGFbeta signalling results in a reduction in metastasis formation. This study is the first study to use a cell line with a low metastatic rate and TGFbetaRII mutations to demonstrate that restoring TGFbeta signalling increases the metastatic rate.
BACKGROUND:TGFbeta is an important cell growth regulator which may have a role in metastasis formation. Microsatellite unstable (MSI-H) colon cancer serves as a unique model to demonstrate this as most MSI-H colon cancers have a mutation in the transforming growth factor beta receptor II (TGFbetaRII) gene and a low metastatic rate. AIMS: To demonstrate an increase in invasion and metastasis in a MSI-H colorectal cancer cell line with a known mutation in TGFbetaRII. MATERIALS AND METHODS: By restoring the wild-type TGFbetaRII gene in the KM12C MSI-H colorectal carcinoma cell line with a known mutation in TGFbetaRII, we have demonstrated that both invasion and metastasis in this cell line was significantly increased. A mouse metastatic model have shown that liver metastases were increased in mice inoculated with cells containing a wild-type TGFbetaRII gene (42% for the transfected group compared with 15% for the control group; p = 0.0379), despite a reduction in the size of primary tumours. CONCLUSIONS: This study highlights an important mechanism which may contribute to the low metastatic rate of MSI-H colon cancers and demonstrates the importance of TGFbeta signalling in metastasis formation. Previous studies involving breast cancer cell lines have shown that blocking TGFbeta signalling results in a reduction in metastasis formation. This study is the first study to use a cell line with a low metastatic rate and TGFbetaRII mutations to demonstrate that restoring TGFbeta signalling increases the metastatic rate.
Authors: L A Aaltonen; P Peltomäki; F S Leach; P Sistonen; L Pylkkänen; J P Mecklin; H Järvinen; S M Powell; J Jen; S R Hamilton Journal: Science Date: 1993-05-07 Impact factor: 47.728
Authors: Catherine E Gatza; Alisha Holtzhausen; Kellye C Kirkbride; Allyson Morton; Michael L Gatza; Michael B Datto; Gerard C Blobe Journal: Neoplasia Date: 2011-08 Impact factor: 5.715
Authors: George S Karagiannis; Ann Treacy; David Messenger; Andrea Grin; Richard Kirsch; Robert H Riddell; Eleftherios P Diamandis Journal: Mol Oncol Date: 2014-04-19 Impact factor: 6.603
Authors: Zhongyan Wang; Megan Snyder; Jessica E Kenison; Kangkang Yang; Brian Lara; Emily Lydell; Kawtar Bennani; Olga Novikov; Anthony Federico; Stefano Monti; David H Sherr Journal: Int J Mol Sci Date: 2020-12-31 Impact factor: 6.208
Authors: Elena Tosti; Ana S Almeida; Tam T T Tran; Mariel Barbachan E Silva; Pilib Ó Broin; Robert Dubin; Ken Chen; Amanda P Beck; Andrew S Mclellan; Eduardo Vilar; Aaron Golden; Paul W O'Toole; Winfried Edelmann Journal: Cell Mol Gastroenterol Hepatol Date: 2022-06-07